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System has a non-metallic design with a pressurized support struc-
ture, which allows precise positioning, retrieval and full hemody-
namic assessment of valve performance prior to permanent
implantation. The DISCOVER registry is a European prospective
multicenter study to evaluate the real-world performance of the DFM
valve for the treatment of severe symptomatic aortic stenosis in
extreme risk patients.
METHODS Patients with a logistic Euro Score  20 or other high
surgical risk co-morbidities not reﬂected by the logistic Euro
Score were enrolled at twenty-two (22) participating centers in
Europe. All endpoint-related adverse events are being adjudicated
by an independent clinical event committee. In this abstract,
we provide a preliminary report on 30d results in 275 patients and
1-year results in the ﬁrst 125 DISCOVER registry patients treated
with a Direct Flow Medical valve. Data from additional patients
will become available shortly and will be included in the
presentation.
RESULTS Patients were 82.65.4 years, and 41% of patients were
female. The logistic Euro Score and STS were 18.914.7% (N¼273) and
8.18.3% (N¼148), respectively. Other co-morbidities included coro-
nary artery disease in 65.1%, prior CABG 16.7%, and chronic kidney
disease 32.4%. In this population, 5.1% (n¼14) of patients received a
23mm valve, 42.5% (n¼117) a 25mm valve, 34.5% (n¼95) a 27mm
valve, and 13.1% (n¼36) a 29mm valve. At 30 days, freedom from all-
cause mortality was 98.2% (270/275) and freedom from death and
major stroke was 96.4% (265/275). A new permanent pacemaker was
implanted in 12.7% (35/275). The rate of major vascular complications
was 3.6% (10/275), and the rate of acute kidney injury stage 2 or 3
was 3.3% (9/275). Paravalvular regurgitation at 30 days was none or
trace in 81.0% (149/184) of patients, moderate in 2.7% (5/184)
and severe in no patients, with 86.4% (159/184) in NYHA functional
class I or II. At the time of abstract submission, 1 year data on 125
patients were available. In this population, freedom from all-cause
mortality at 1 year was 87.2% (109/125) and freedom from all-cause
mortality and major stroke was 82.4% (103/125). A new permanent
pacemaker was implanted in 2.4% (3/125) of these patients between
30 days and 1 year. Paravalvular regurgitation was none or trace in
91.4% (64/70) of patients, moderate in 1.4% (1/70) and severe in no
patients, and 84.0% (68/81) of patients were in NYHA functional class
I or II at 1 year.
CONCLUSIONS The Direct Flow Medical Trans-catheter Aortic Valve
System demonstrates excellent real-world outcomes in extreme sur-
gical risk patients with severe aortic stenosis.
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BACKGROUND Recently, a robotic system for performing remote-
controlled angioplasty and stent placement was approved for clinical
use in the US. This robotic system allows the operator to perform
percutaneous coronary intervention (PCI) while seated in a lead-lined
cockpit, thereby minimizing radiation exposure and eliminating the
need for lead apparel. To date, available data describing robotic PCI
have been obtained exclusively using femoral arterial access. This
study was performed to describe the initial clinical experience and
procedure outcomes of robotic PCI performed using radial arterial
access.
METHODS Data were collected from consecutive robotic PCI cases
performed at a single center using radial arterial access. Target
coronary lesions were classiﬁed angiographically according to the
ACC/AHA lesion classiﬁcation system. The primary measure of in-
terest was procedure success, deﬁned as <30% residual stenosis
after PCI in the absence of associated death or repeat revasculari-
zation prior to hospital discharge. Access site complications,
including bleeding or radial artery occlusion, were assessed.Procedure duration, deﬁned as the time from sheath insertion to
removal of the guide catheter, was recorded and compared to all
manual PCI cases performed at the same center using radial arterial
access during the same time period.
RESULTS We studied 55 consecutive patients (age 62  11; 78%
male) undergoing robotic PCI using radial arterial access. The clinical
presentation of these patients was myocardial infarction in 31%,
unstable angina in 60%, and stable symptoms in 9%. Robotic PCI
was attempted on 62 lesions overall, with varying baseline angio-
graphic complexities (Type A 19%, Type B1 27%, Type B2 34%, Type
C 19%). Robotic PCI resulted in procedure success in 57 of 62 (92%)
lesions. In 4 of 5 cases in which procedure success was not achieved,
lesions were classiﬁed as ACC/AHA Type C. None of the patients
undergoing robotic PCI experienced death or repeat revasculariza-
tion prior to hospital discharge and there were no access site com-
plications. Robotic PCI was associated with a 13-minute increase in
procedure duration compared to 552 consecutive PCI cases per-
formed manually from the radial approach during the same time
period (robotic PCI 68  22 minutes vs. manual PCI 55  26 minutes;
p<0.001).
CONCLUSIONS The present observations represent preliminary evi-
dence that robotic PCI using radial arterial access is feasible and
associated with acceptable clinical outcomes. Additional studies are
needed to further evaluate the clinical outcomes associated with ro-
botic PCI and to determine if robotic PCI procedure duration, which
we demonstrate to be longer than the traditional manual approach in
this early clinical experience, will shorten as additional clinical
experience is gained.
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BACKGROUND The repositionable and fully retrievable Lotus
Valve (Boston Scientiﬁc, Marlborough, MA, USA) was designed to
facilitate accurate positioning and minimize paravalvular regurgita-
tion in patients with severe aortic stenosis. This analysis will present
the ﬁrst report of 2-year outcomes from the REPRISE II CE-Mark
study.
METHODS The REPRISE II study is a prospective, single-arm trial that
enrolled patients who are at high or extreme surgical risk and
aged 70 years at 14 centers in Australia and Europe. Patients had
severe, symptomatic calciﬁc aortic stenosis and were deemed to be at
high or extreme risk for surgery based on assessment by the Heart
Team.
RESULTS Among 120 enrolled patients, the mean age was 84.45.3
years, 57% (68/120) were female, and mean STS Score was 7.14.6.
The mean baseline aortic valve area was 0.70.2cm2 and the mean
aortic valve pressure gradient was 46.415.0mmHg. All patients
were successfully implanted with a Lotus Valve; full valve retrieval
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primary performance endpoint of 30-day mean aortic valve pressure
gradient was 11.55.2mmHg, as assessed by an independent core lab,
and was signiﬁcantly less than the performance goal of 18 mmHg
(P<0.001). The primary safety endpoint of 30-day all-cause mortality
was 4.2%. One-year follow-up data or death was available for 99.2%
(119/120) of patients (1 patient withdrew consent at day 13). At 1 year,
the rate of all-cause mortality was 10.9% (13/119), disabling stroke
was 3.4% (4/119), and disabling bleeding was 5.9% (7/119). There
were no repeat procedures for valve-related dysfunction, valve
migration, embolization, or TAV-in-TAV. A total of 31.9% (38/119)
patients had new permanent pacemaker implantation due to
new or worsened conduction disturbance. By independent core
lab adjudication, the 1-year mean aortic valve gradient was
12.65.7mmHg and mean aortic valve area was 1.70.5cm2. A total
of 88.6% patients had no or trivial paravalvular aortic regurgitation
at 1 year; no patient had moderate or severe paravalvular aortic
regurgitation.
CONCLUSIONS The Lotus Valve has demonstrated negligible para-
valvular regurgitation and low rates of death and stroke at 1 year.
The 2-year results of the REPRISE II CE-Mark trial will provide the
longest follow-up to date in the full cohort of 120 patients treated
with the Lotus Valve; results will be available for the ﬁrst time at
TCT 2015.
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BACKGROUND The Cardioband system enables percutaneous im-
plantation of an adjustable “surgical-like” mitral annuloplasty ring
using a transseptal approach. The aim of this study was to evaluate
the feasibility, safety and up to 12 month outcome of Cardioband in
patients with secondary mitral regurgitation (MR) in a multicentre
study.
METHODS Between February 2013 and March 2015, 40 high-risk pa-
tients with signiﬁcant secondary MR were enrolled at 6 sites in
Europe. After a Heart Team evaluation all patients were screened by
echocardiography and cardiac CT to assess feasibility. Echocardio-
graphic data were analyzed by an independent core-lab. Mean age was
727 years; thirty patients were male (75%). Mean EuroScore II 9.0%
7.02% and median STS score 7.2 % (1.0%-34.0%). At baseline 93% of
patients were in NYHA class III-IV with mean left ventricular ejection
fraction of 33.310% (15%-57%). Device implantation was feasible in
all patients (100%).
RESULTS Acute procedural success (device successfully implanted
with acute reduction of MR <2þ) was achieved in 92% of the
patients (37/40). After cinching of the device, an average 20%
reduction in the septo-lateral diameter was observed (from 375 mm
to 295 mm; p<0.01). Thirty-day mortality was 5.0% (adjudicated as
unrelated to the device). At 6-month follow-up (N¼20) 80% of
patients were in NYHA class I-II with signiﬁcant improvement
in quality of life (MLWHFQ from 38 to 18; p<0.05) and 85% of
patients had MR2þ. At 12 month follow-up (N¼14), 70% of
patients were in NYHA class I-II with signiﬁcant improvement in
quality of life (MLWHFQ from 35 to 17; p<0.05 and signiﬁcant
improvement in 6MW from 288 m to 360 m; p<0.05); 93% of pa-
tients had MR<2þ).CONCLUSIONS Transseptal direct annuloplasty with an adjustable
“surgical-like” ring is feasible, with a comparable safety proﬁle similar
to other transcatheter mitral procedures. Effective reduction in MR
severity is observed in most patients related to a signiﬁcant septo-
lateral dimension reduction. MR reduction is stable and consistent up
to 12 months, with clinical beneﬁt.
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BACKGROUND Mitral regurgitation (MR) frequently accompanies
aortic stenosis (AS). Transcatheter aortic valve replacement (TAVR) is
an effective treatment for severe AS, but unlike surgical treatment,
cannot simultaneously address MR. The impact of concomitant MR on
TAVR outcomes requires better understanding, as does the impact of
TAVR on MR severity.
METHODS Patients who underwent TAVR between 1/2012 and 12/2013
in the STS-ACC TVT registry were analyzed for baseline and proce-
dural characteristics, in-hospital and 30 day clinical outcomes as well
as echo outcomes. Center for Medicare and Medicaid Services data
was obtained for longer-term outcomes.
RESULTS Of 11,221 patients who underwent TAVR, 3,497 (31%) had
baseline moderate (2þ) MR and 602 (5%) had severe (3 to 4þ) MR.
As compared to patients with minimal MR (0, trace, or 1þ),
patients with moderate or severe MR were older, more often female,
more likely NYHA class III-IV, had more atrial ﬁbrillation/ﬂutter, and
were more likely to have a preoperative pacemaker. Patients with
minimal MR had more diabetes, chronic severe lung disease, and
need for home O2. Echo/cath showed patients with moderate or
severe MR had lower ejection fractions, higher pulmonary artery
systolic and wedge pressures. STS predicted 30-day mortality in
minimal, moderate and severe MR patients were 8.1%, 9.6% and
10.7% respectively (p < 0.0001). MR improved at least 1 grade on
post-procedure (pre-discharge) echocardiogram in 79% of the severe
MR patients and 66% of the moderate MR patients. Unadjusted
death at 30 days in the minimal, moderate and severe MR patients
was 6.7%, 8.5% and 12.6%, respectively (p<0.0001). Unadjusted
death at 1 year was 22.3%, 27.1% and 28.2%, respectively (p<0.0001).
(Figure)
CONCLUSIONS Approximately one-third of patients presenting
for TAVR in US have moderate to severe preoperative MR.
